CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-01). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1902 · Search date 2026-08-01 · Methodology v0.6

Prednisolone,
does it really help with Analgesic equivalence to indomethacin or naproxen in adult acute gout?

30-Second Summary
C
Evidence Grade C · 55 · Safety caution
Prednisolone performed similarly to NSAIDs in two trials, but the evidence is limited to active-control equivalence designs
Even short courses can cause hyperglycemia, insomnia, mood changes, and gastrointestinal upset; diabetes, infection, and peptic-ulcer risk require individualized supervision.
What the
research shows
The grade is C. Active-control equivalence trials found pain reduction similar to indomethacin or naproxen. No randomized trial of systemic glucocorticoid alone versus placebo in acute gout was identified, so the evidence supports comparative equivalence rather than absolute analgesic efficacy; the score is C with 55 points.
What the
ads claim
Similar performance against an NSAID should not be restated as two direct placebo-controlled demonstrations of absolute benefit. Its role as an alternative when NSAIDs are unsuitable also needs clinical context.
*

Useful facts when choosing a product

  • Prednisolone is a systemic glucocorticoid prescription drug.
  • Existing prednisolone verdicts concern Bell's palsy, alcoholic hepatitis, lower respiratory infection, and sudden hearing loss rather than acute gout.
  • The trial regimens were short courses of about five days and do not replace long-term urate-lowering therapy.
Gap Measurement · Verdict 1902 · C 55
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Rainer 2016 was a double-blind double-dummy active-control equivalence trial comparing prednisolone with indomethacin. Janssens 2008 compared prednisolone with naproxen and used a 118-participant completer primary analysis. Janssens was also an author on Rainer, so these do not represent separate-investigator replication.

02

Why this is classified as C (55)

Overlapping investigators and the two shared defects—equivalence design and active controls without placebo—give C with 55 points.

Counterpoint. C does not mean no effect; it reflects that the confirmed comparison is equivalence to NSAIDs rather than direct placebo superiority.

Rejudgment record. Cross-check applied — The two active-control equivalence trials shared an investigator, and no systemic-glucocorticoid-alone placebo trial was identified

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Pain relief equivalent to indomethacin at two hoursCThe result was within the 13-mm boundary, but there was no placebo arm.
Pain relief equivalent to naproxen at 90 hoursCThe 118-participant primary analysis met the prespecified equivalence range.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Multicenter double-blind double-dummy randomized active-control equivalence trial187Hong Kong Government Health and Health Services Research Grant CommitteeTwo-hour change in 100-mm VAS pain at rest and with activity; prespecified equivalence margin 13 mmBetween-group difference -1.15 mm at rest (95% CI -3.14 to 0.83), P=0.79, and 0.10 mm with activity (-1.91 to 2.10), P=0.52; equivalence met.Pivotal publicly funded active-control equivalence trial
Study 2Double-blind randomized active-control equivalence trial59Academic study at Radboud University Nijmegen Medical CentreReduction in 100-mm VAS pain at 90 hours; prespecified equivalence range 10 mmReductions of 44.7 versus 46.0 mm, difference 1.3 mm (95% CI -9.8 to 7.1).Equivalence trial sharing an investigator with Rainer
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-01).

Rainer TH, Cheng CH, Janssens HJEM, et al. Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. Ann Intern Med. 2016;164(7):464-471. PMID: 26903390. DOI: 10.7326/M14-2070.
checked
Janssens HJEM, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis. Lancet. 2008;371:1854-1860. PMID: 18514729. DOI: 10.1016/S0140-6736(08)60799-0.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-01 · Corrections: none

Cite this verdict

Prednisolone x analgesic equivalence to indomethacin or naproxen in acute gout Evidence Grade C card
[Chamgap] Prednisolone x analgesic equivalence to indomethacin or naproxen in acute gout — Evidence Grade C·55. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/oral-prednisolone-acute-gout-pain-relief/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.